DUBLIN–(BUSINESS WIRE)–The “Genome Editing Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Technology, Application, and End User” report has been added to ResearchAndMarkets.com’s offering.
The genome editing market is projected to reach US$ 16,986.69 million by 2028 from US$ 5,199.40 million in 2021; it is expected to grow at a CAGR of 18.4% from 2021 to 2028.
Over the past few years, advances in genome editing technologies have been making constant headlines. Genome editing technologies can alter biological research and significantly impact human health, food security, and environmental sustainability since they are precise, relatively inexpensive, easy to use, and remarkably powerful. The advances in genome editing can be traced back to quiet beginnings in the 1990s.
The introduction of CRISPR-Cas9 – a genome-editing tool that can be used to make precise and targeted changes in the DNA sequence with ease – is mainly responsible for the recent rise in the amount and scope of applications of genome editing technologies. The CRISPR platform’s ease of use, as compared to previous technologies, has resulted in its widespread adoption and application. Genome editing could have a favorable impact on sustainable development, environmental management, food security, and the introduction of affordable diagnostics and therapies for various diseases due to these advancements.
A team from MIT and Harvard’s Broad Institute has developed a novel CRISPR genome-editing technique that has the potential to fix up to 89% of disease-causing genetic abnormalities. CRISPR-Cas9 and reverse transcriptase, two of the most significant proteins in molecular biology, have been merged into a single machine by researchers.
Prime editing is a method that can alter human cells directly in a precise, efficient, and highly versatile manner. They have also developed a CRISPR RNA-cutting enzyme into an antiviral agent that can be programmed to detect and eliminate RNA-based viruses in human cells. The Cas13 enzyme has previously been used to cut and alter human RNA and as a diagnostic approach for detecting the presence of viruses, bacteria, and other targets. This is one of the first studies to use Cas13, or any CRISPR system, as an antiviral in human cells in culture.
Recognizing the potential of genome editing techniques for studying and manipulating the genome., the Department of Biotechnology (DBT), Govt. of India has been fostering research and innovation in genome engineering technologies and applications to make them more accessible and inexpensive for research and development ( R&D).
Through focused calls for proposals in different areas such as the development of new methods, tools, processes, and platforms for genome editing, improvement of existing genome-editing methods, and novel applications of genome editing technologies in agriculture, bioenergy, environmental research, and human health, efforts have been made to encourage R&D programs in emerging genome engineering technologies and their applications.
Market Dynamics
Market Drivers
- Rise in Prevalence of Cancer and Other Genetic Disorders
- Continuous Technological Advancements in Gene-Editing Tools
Market Restraints
- High Cost of Genomic Equipment
Market Opportunities
- Developing Biotechnology Industry in Emerging Regions
Future Trends
-
Technological Innovations
Key Topics Covered:
1. Introduction
2. Genome Editing Market- Key Takeaways
3. Research Methodology
4. Genome Editing Market- Market Landscape
5. Genome Editing Market – Key Market Dynamics
6. Genome Editing Market- Global Analysis
7. Global Genome Editing Market Revenue and Forecasts To 2028- by Technology
8. Genome Editing Market Revenue and Forecasts To 2028 – Application
9. Genome Editing Market Revenue and Forecasts To 2028 – End User
10. Genome Editing Market Revenue and Forecasts to 2028 – Geographical Analysis
11. Impact Of COVID-19 Pandemic on Genome Editing Market
12. Genome Editing Market-Industry Landscape
13. Company Profiles
14. Appendix
Companies Mentioned
- THERMO FISHER SCIENTIFIC INC.
- MERCK KGaA
- Lonza
- Horizon Discovery Group plc.
- Integrated DNA Technologies
- GenScript
- New England Biolabs
- Eurofins Scientific
- CRISPR Therapeutics
- Editas Medicine
For more information about this report visit https://www.researchandmarkets.com/r/z2omnl
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900